Search research articles
Contact Us
Filters
Showing results (531-540 of 545) with videos related to
Page
of 55
Sort By:
Journal of Medicinal Chemistry
|
October 24, 2014
Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models
Snahel Patel, Frederick Cohen, Brian J Dean, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349
Zhonghua Pei, Elizabeth Blackwood, Lichuan Liu, et al.
Science Immunology
|
November 8, 2024
Macrophage LRRK2 hyperactivity impairs autophagy and induces Paneth cell dysfunction
Shengxiang Sun, Miki Hodel, Xiang Wang, et al.
Journal of Medicinal Chemistry
|
March 30, 2018
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling
Huifen Chen, Matthew Volgraf, Steven Do, et al.
JRSM Cardiovascular Disease
|
June 22, 2023
Comparison of the use of blood pressure telemonitoring versus standard medical care in the achievement of short-term therapeutic goals in blood pressure in patients with uncontrolled hypertension: An open-label clinical trial
M G Ramos-Zavala, F Grover-Páez, E G Cardona-Muñoz, et al.
Science Translational Medicine
|
February 6, 2015
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N Fuji, Michael Flagella, Miriam Baca, et al.
Molecular Neurodegeneration
|
August 7, 2025
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome
Michael T Maloney, Xiang Wang, Rajarshi Ghosh, et al.
Journal of Medicinal Chemistry
|
December 21, 2013
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
Anthony A Estrada, Bryan K Chan, Charles Baker-Glenn, et al.
Science Translational Medicine
|
April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
Marco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
Elife
|
September 17, 2024
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response
Ernie Yulyaningsih, Jung H Suh, Melania Fanok, et al.
Page
of 55
Search research articles
Search
Showing results (531-540 of 545) with videos related to
Sort By:
Page
of 55
Journal of Medicinal Chemistry
|
October 24, 2014
Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models
Snahel Patel, Frederick Cohen, Brian J Dean, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349
Zhonghua Pei, Elizabeth Blackwood, Lichuan Liu, et al.
Science Immunology
|
November 8, 2024
Macrophage LRRK2 hyperactivity impairs autophagy and induces Paneth cell dysfunction
Shengxiang Sun, Miki Hodel, Xiang Wang, et al.
Journal of Medicinal Chemistry
|
March 30, 2018
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling
Huifen Chen, Matthew Volgraf, Steven Do, et al.
JRSM Cardiovascular Disease
|
June 22, 2023
Comparison of the use of blood pressure telemonitoring versus standard medical care in the achievement of short-term therapeutic goals in blood pressure in patients with uncontrolled hypertension: An open-label clinical trial
M G Ramos-Zavala, F Grover-Páez, E G Cardona-Muñoz, et al.
Science Translational Medicine
|
February 6, 2015
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N Fuji, Michael Flagella, Miriam Baca, et al.
Molecular Neurodegeneration
|
August 7, 2025
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome
Michael T Maloney, Xiang Wang, Rajarshi Ghosh, et al.
Journal of Medicinal Chemistry
|
December 21, 2013
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
Anthony A Estrada, Bryan K Chan, Charles Baker-Glenn, et al.
Science Translational Medicine
|
April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
Marco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
Elife
|
September 17, 2024
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response
Ernie Yulyaningsih, Jung H Suh, Melania Fanok, et al.
Page
of 55